Total Payments
$5,018
2023 Payments
$44.08
Companies
22
Transactions
205
Medicare Patients
1,758
Medicare Billing
$132,197
Payment Breakdown by Category
Food & Beverage$4,979 (99.2%)
Education$39.50 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,979 | 200 | 99.2% |
| Education | $39.50 | 5 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $1,066 | 95 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $922.58 | 25 | $0 (2023) |
| Biohaven Pharmaceutical Holding Company Ltd. | $360.64 | 9 | $0 (2022) |
| Novo Nordisk Inc | $350.17 | 9 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $343.37 | 5 | $0 (2022) |
| ABBVIE INC. | $290.42 | 28 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $281.51 | 4 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $232.70 | 4 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $177.75 | 2 | $0 (2019) |
| Amarin Pharma Inc. | $127.86 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $44.08 | 3 | AstraZeneca Pharmaceuticals LP ($17.56) |
| 2022 | $625.61 | 14 | Biohaven Pharmaceutical Holding Company Ltd. ($360.64) |
| 2021 | $748.66 | 35 | Biohaven Pharmaceuticals, Inc. ($281.51) |
| 2020 | $457.49 | 30 | Allergan, Inc. ($258.14) |
| 2019 | $932.84 | 45 | Allergan Inc. ($377.82) |
| 2018 | $1,156 | 42 | Allergan Inc. ($322.70) |
| 2017 | $1,054 | 36 | AstraZeneca Pharmaceuticals LP ($339.09) |
All Payment Transactions
205 individual payment records from CMS Open Payments — Page 2 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: PRIMARY CARE | ||||||
| 09/02/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.52 | General |
| Category: NEUROSCIENCE | ||||||
| 08/31/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: NEUROSCIENCE | ||||||
| 08/25/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $124.79 | General |
| Category: PRIMARY CARE | ||||||
| 08/24/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.25 | General |
| Category: NEUROSCIENCE | ||||||
| 08/18/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $73.13 | General |
| Category: NEUROSCIENCE | ||||||
| 07/29/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.43 | General |
| Category: NEUROSCIENCE | ||||||
| 07/13/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $110.40 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/24/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $123.88 | General |
| Category: PRIMARY CARE | ||||||
| 06/14/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.21 | General |
| Category: NEUROSCIENCE | ||||||
| 06/03/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: Respiratory | ||||||
| 05/27/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $7.45 | General |
| Category: NEUROSCIENCE | ||||||
| 05/18/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.61 | General |
| Category: NEUROSCIENCE | ||||||
| 05/17/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.04 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.74 | General |
| Category: NEUROSCIENCE | ||||||
| 04/27/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.47 | General |
| Category: NEUROSCIENCE | ||||||
| 04/19/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.84 | General |
| Category: NEUROSCIENCE | ||||||
| 03/26/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $9.09 | General |
| Category: NEUROSCIENCE | ||||||
| 03/16/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.22 | General |
| Category: NEUROSCIENCE | ||||||
| 02/12/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug), FARXIGA | Food and Beverage | In-kind items and services | $43.42 | General |
| Category: Respiratory | ||||||
| 02/08/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.75 | General |
| Category: NEUROSCIENCE | ||||||
| 02/08/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.96 | General |
| Category: NEUROSCIENCE | ||||||
| 02/02/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $3.96 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 335 | 470 | $60,615 | $29,355 |
| 2022 | 8 | 426 | 596 | $63,565 | $35,236 |
| 2021 | 9 | 472 | 629 | $64,985 | $36,118 |
| 2020 | 10 | 525 | 722 | $71,901 | $31,488 |
Total Patients
1,758
Total Services
2,417
Medicare Billing
$132,197
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 74 | 175 | $21,875 | $10,390 | 47.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 63 | 63 | $17,325 | $7,864 | 45.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 69 | 90 | $13,520 | $6,755 | 50.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 29 | 42 | $4,200 | $1,469 | 35.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 16 | 16 | $1,235 | $1,181 | 95.6% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 66 | 66 | $1,650 | $1,166 | 70.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 18 | 18 | $810.00 | $530.10 | 65.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 63 | 180 | $18,025 | $10,652 | 59.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 85 | 123 | $17,220 | $9,791 | 56.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 60 | 60 | $16,085 | $7,724 | 48.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 29 | 29 | $2,320 | $2,037 | 87.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 33 | 48 | $6,000 | $2,016 | 33.6% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 63 | 63 | $1,260 | $1,152 | 91.4% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 64 | 64 | $1,915 | $1,150 | 60.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 29 | 29 | $740.00 | $714.29 | 96.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 85 | 211 | $21,100 | $11,787 | 55.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 70 | 70 | $18,900 | $9,216 | 48.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 74 | 103 | $14,420 | $8,633 | 59.9% |
| 90682 | Vaccine for influenza derived from dna for injection into muscle, quadrivalent, preservative and antibiotic free | Office | 2021 | 29 | 29 | $2,030 | $1,893 | 93.2% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2021 | 76 | 76 | $1,520 | $1,397 | 91.9% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 74 | 74 | $2,220 | $1,360 | 61.3% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 15 | 16 | $1,770 | $670.72 | 37.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 18 | 19 | $2,250 | $652.68 | 29.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 31 | 31 | $775.00 | $508.40 | 65.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 98 | 178 | $25,050 | $11,554 | 46.1% |
About Dr. Oscar Reyna, MD
Dr. Oscar Reyna, MD is a General Practice healthcare provider based in Latrobe, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063408706.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Oscar Reyna, MD has received a total of $5,018 in payments from pharmaceutical and medical device companies, with $44.08 received in 2023. These payments were reported across 205 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($4,979).
As a Medicare-enrolled provider, Reyna has provided services to 1,758 Medicare beneficiaries, totaling 2,417 services with total Medicare billing of $132,197. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Location Latrobe, PA
- Active Since 09/27/2005
- Last Updated 05/21/2021
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1063408706
Products in Payments
- VRAYLAR (Drug) $650.82
- NURTEC ODT (Drug) $642.15
- FARXIGA (Drug) $576.11
- XARELTO (Drug) $343.37
- UBRELVY (Drug) $286.65
- ENTRESTO (Drug) $232.70
- LINZESS (Drug) $227.91
- BYDUREON (Drug) $192.93
- Xultophy 100/3.6 (Drug) $189.26
- AUSTEDO (Drug) $177.75
- Ozempic (Drug) $131.93
- Vascepa (Drug) $127.86
- INGREZZA (Drug) $112.46
- TRULICITY (Drug) $111.99
- Movantik (Drug) $108.53
- LifeVest (Device) $99.62
- ELIQUIS (Drug) $94.13
- EUCRISA (Drug) $92.09
- WATCHMAN (Device) $83.02
- MOVANTIK (Drug) $81.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Latrobe
Dr. Scott Learn, D.m.d, D.M.D
General Practice — Payments: $3,067
General Practice $3,067
Dr. Kurt Washnock, Dmd, DMD
General Practice — Payments: $2,013
General Practice $2,013
Scott Hudimac, Dds, DDS
General Practice — Payments: $1,272
General Practice $1,272
Scott Salancy, D.m.d, D.M.D
General Practice — Payments: $517.66
General Practice $517.66
Dr. John Rawa, Dmd, DMD
General Practice — Payments: $350.01
General Practice $350.01
Dr. James Bryan, Dmd, DMD
General Practice — Payments: $242.46
General Practice $242.46